Safety of adjuvant aromatase inhibitor therapy

Cancer Treatment Reviews

Volumn 32, Issue 7, 2006, Pages 548-556

  Venturini, M ^a   Del Mastro, L ^b  

^a Ospedale Sacro Cuore Don Calabria   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

Author keywords

Adjuvant aromatase inhibitors; Anastrozole; BIG 1 98 trial; Breast cancer; Estrogen deprivation; Exemestane; Letrozole; MA.17 trial; Safety; Tamoxifen

Indexed keywords

ANASTROZOLE; AROMATASE INHIBITOR; BISPHOSPHONIC ACID DERIVATIVE; CHOLESTEROL; ESTROGEN; EXEMESTANE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LETROZOLE; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; TAMOXIFEN CITRATE; TRIACYLGLYCEROL; ZOLEDRONIC ACID;

ARTHRALGIA; ARTHRITIS; BACKACHE; BODY WEIGHT DISORDER; BONE DISEASE; BREAST CANCER; CANCER ADJUVANT THERAPY; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COGNITIVE DEFECT; DEEP VEIN THROMBOSIS; DIARRHEA; DISEASE FREE SURVIVAL; DIZZINESS; DRUG ERUPTION; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSLIPIDEMIA; ENDOMETRIUM CANCER; FATIGUE; FOLLOW UP; FRACTURE; GASTROINTESTINAL DISEASE; GYNECOLOGIC DISEASE; HAIR LOSS; HEADACHE; HEART INFARCTION; HEART PROTECTION; HOT FLUSH; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; HYPERTENSION; INFORMATION PROCESSING; ISCHEMIC HEART DISEASE; LIMB PAIN; MEDICAL DECISION MAKING; MEDICAL INFORMATION; MEDICAL RESEARCH; MOOD DISORDER; MUSCULOSKELETAL PAIN; MYALGIA; NAUSEA AND VOMITING; OSTEOARTHRITIS; OSTEOLYSIS; OSTEOPOROSIS; QUALITY OF LIFE; REVIEW; RISK ASSESSMENT; STOMACH ULCER; THROMBOEMBOLISM; TREATMENT DURATION; TREATMENT OUTCOME; VAGINA BLEEDING; VAGINA DISCHARGE; VISUAL DISORDER; WEIGHT GAIN;

AROMATASE INHIBITORS; ARTHRITIS; BREAST NEOPLASMS; CARDIOVASCULAR DISEASES; CLINICAL TRIALS; CLINICAL TRIALS AS TOPIC; FEMALE; FRACTURES, BONE; GENITAL DISEASES, FEMALE; HUMANS; LIPID METABOLISM; NEOADJUVANT THERAPY; OSTEOPETROSIS;

EID: 33749077505     PISSN: 03057372     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ctrv.2006.07.012     Document Type: Review

References (60)

1. Thürlimann B., Keshaviah A., Coates A.S., et al., Breast International Group (BIG) 1-98 Collaborative Group. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 353 (2005) 2747-2757
2. Howell A., Cuzick J., Baum M., et al., ATAC Trialists' Group. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 365 (2005) 60-62
3. Coombes R.C., Paridaens R., Jassem J., et al. First mature survival analysis of the Intergroup Exemestane Study (IES). J Clin Oncol 24 18S (2006) 9s [abstract LBA527]
4. Goss P.E., Ingle J.N., Martino S., et al. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA 17. J Natl Cancer Inst 97 (2005) 1262-1271
5. Robert N.J., Goss P.E., Ingle J.N., et al. Updated analysis of NCIC CTG MA.17 (letrozole vs. placebo to letrozole vs. placebo) post unblinding. J Clin Oncol 24 18S (2006) 15s [abstract 550]
6. Coleman R.E., and On behalf of the ATAC Trialists' Group. Effect of anastrozole on bone mineral density: 5-year results from the 'Arimidex', Tamoxifen, Alone or in Combination (ATAC) trial. J Clin Oncol 24 18S (2006) 5s [abstract 511]
7. Melton L.J., Chrischilles E.A., Cooper C., Lane A.W., and Riggs B.L. Perspective. How many women have osteoporosis?. J Bone Mineral Res 7 (1992) 1005-1010
8. National Institutes of Health. Osteoporosis and Related Bone Disorders National Resource Center. Osteoporosis Overview. Bethesda, MD, US Department of Health and Human Services; 2003.
9. International Osteoporosis Foundation. Osteoporosis in the European Community: Action Plan. A report of the key next steps towards a Europe free from fragility fractures. Presented on November 12, 2003 by the European Union Osteoporosis Consultation Panel at the European Parliament in Brussels. Available from: http://www.osteofound.org/advocacy_policy/eu_policy_project/pdf/action_plan_03_3.pdf. Accessed December 23; 2005.
10. Perez E.A., Josse R.G., Pritchard K.I., et al. Effect of letrozole versus placebo on bone mineral density in women completing 5 years of adjuvant tamoxifen: NCIC CTG MA 17b. Breast Cancer Res Treat 88 Suppl. 1 (2004) 404a [abstract 404]
11. Lønning P.E., Geisler J., Krag L.E., et al. Changes in bone metabolism after 2 years treatment with exemestane (E) in postmenopausal women with early breast cancer (EBC) at low risk: follow-up (FU) results of a randomized placebo-controlled study. J Clin Oncol 23 (2005) 11S [abstract 531]
12. Howell A. Effect of anastrozole on bone mineral density: 2-year results of the Arimidex (anastrozole), tamoxifen, alone or in combination (ATAC) trial. Breast Cancer Res Treat 82 Suppl. 1 (2003) 129a [abstract 129]
13. Lester J., Dodwell D., McCloskey E., and Coleman R. The causes and treatment of bone loss associated with carcinoma of the breast. Cancer Treat Rev 31 (2005) 115-142
14. Johannessen D.C., Engan T., Di Salle E., et al. Endocrine and clinical effects of exemestane (PNU 155971), a novel steroidal aromatase inhibitor, in postmenopausal breast cancer patients: a phase I study. Clin Cancer Res 3 (1997) 1101-1108
15. Coleman R.E. Skeletal effect of exemestane in the Intergroup Exemestane Study (IES) - 2 year bone mineral density (BMD) and bone biomarker data. Breast Cancer Res Treat 94 Suppl. 1 (2005) S233 [abstract 5076]
16. Lønning P.E., Geisler J., Krag L.E., et al. Effects of exemestane administered for 2 years versus placebo on bone mineral density, bone biomarkers, and plasma lipids in patients with surgically resected early breast cancer. J Clin Oncol 23 (2005) 5126-5137
17. Rubin C.D. Emerging concepts in osteoporosis and bone strength. Curr Med Res Opin 21 (2005) 1049-1056
18. Arimidex full prescribing information. AstraZeneca Pharmaceuticals LP, Wilmington, Delaware. Revised September 2005.
19. Jakesz R., Jonat W., Gnant M., et al., On behalf of the ABCSG, the GABG. Switching of postmenopausal women with endocrine responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial. Lancet 366 (2005) 455-462
20. Aromasin full prescribing information. Pharmacia Corporation, Kalamazoo, Michigan; 2005.
21. Howell A., and On behalf of the ATAC Trialists' Group. Analysis of fracture risk factors from the 'Arimidex', Tamoxifen, Alone or in Combination (ATAC) trial: 5-year data. J Clin Oncol 24 18S (2006) 18s [abstract 563]
22. Reginster J.Y. The high prevalence of inadequate serum vitamin D levels and implications for bone health. Curr Med Res Opin 21 (2005) 579-586
23. Brufsky A., Harker G., Beck T., et al. Zoledronic acid (ZA) effectively inhibits cancer treatment-induced bone loss (CTIBL) in postmenopausal women (PMW) with early breast cancer (BCa) receiving adjuvant Letrozole (Letrozole): 12 mos BMD results of the Z-FAST trial. J Clin Oncol 23 (2005) 12S [abstract 533]
24. Winer E.P., Hudis C., Burstein H.J., et al. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004. J Clin Oncol 23 (2005) 619-629
25. National Institutes of Health. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Final Report. NIH Publication 02-5215. Bethesda, MD, National Heart, Lung, and Blood Institute, September 2002.
26. Mannucci P.M., Bettega D., Chantarangkul V., Tripodi A., Sacchini V., and Veronesi U. Effect of tamoxifen on measurements of hemostasis in healthy women. Arch Intern Med 156 (1996) 1806-1810
27. Herrington D.M., and Klein K.P. Effects of SERMs on important indicators of cardiovascular health: lipoproteins, hemostatic factors, and endothelial function. Women's Health Issues 11 (2001) 95-102
28. Boccardo F., Rubagotti A., Puntoni M., et al. Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: preliminary results of the Italian Tamoxifen Anastrozole Trial. J Clin Oncol 23 (2005) 5138-5147
29. Markopoulos C., Polychronis A., Zobolas V., et al. The effect of exemestane on the lipidemic profile of postmenopausal early breast cancer patients: preliminary results of the TEAM Greek sub-study. Breast Cancer Res Treat 93 (2005) 61-66
30. Lønning P.E., Geisler J., Krag L., et al. Lipid profile and homocysteine levels in postmenopausal women with early breast cancer at low risk treated for two years with exemestane: follow-up results of a randomized, placebo-controlled study. Breast Cancer Res Treat 94 Suppl. 1 (2005) S203 [abstract 4108]
31. Wasan K.M., Goss P.E., Pritchard P.H., et al. The influence of letrozole on serum lipid concentrations in postmenopausal women with primary breast cancer who have completed 5 years of adjuvant tamoxifen (NCIC CTG MA.17L). Ann Oncol (2005) 707-715 Epub 2005 April 7
32. Markopoulos C., Chrissochou M., Michailidou A., et al. Effect of exemestane on the lipidemic profile of post-menopausal operable breast cancer patients following 5-7 years of adjuvant tamoxifen: preliminary results of the ATENA substudy. Anticancer Drugs 16 (2005) 879-883
33. McCloskey E., Eastell R., Lakner G., Miyamoto A., and Clack G. Initial results from the LEAP study: the first direct comparison of safety parameters between aromatase inhibitors in healthy postmenopausal women. Breast Cancer Res Treat 94 Suppl. 1 (2005) S101 [abstract 2052]
34. American Heart Association. Heart disease and stroke statistics - 2005 update. Dallas (TX): American Heart Association; 2005.
35. National Center for Health Statistics. Health, United States, With Chartbook on Trends in the Health of Americans. US Department of Health and Human Services, Hyattsville, MD; 2005.
36. Peterson S, Peto V, Rayner M, et al. European cardiovascular disease statistics. 2005 edition. London: British Heart Foundation. Available from: http://www.heartstats.org. Accessed September 13; 2005.
37. Fisher B., Costantino J.P., Wickerham D.L., et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 90 (1998) 1371-1388
38. Braithwaite R.S., Chlebowski R.T., Lau J., George S., Hess R., and Col N.F. Meta-analysis of vascular and neoplastic events associated with tamoxifen. J Gen Intern Med 18 (2003) 937-947
39. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365 (2005) 1687-1717
40. Coombes R.C., Hall E., Snowdon C.F., Bliss J.M., and Intergroup Exemestane Study. A randomized trial in postmenopausal women with primary breast cancer who remain disease free after two to three years of tamoxifen: updated survival analysis. Breast Cancer Res Treat 88 Suppl. 1 (2004) S7 [abstract 3]
41. Femara package insert. Novartis Pharmaceuticals Corporation, East Hanover, NJ, October 2005.
42. Goldhirsch A., Glick J.H., Gelber R.D., Coates A.S., Thurlimann B., and Senn H.J. Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005. Ann Oncol 16 (2005) 1569-1583
43. De Boer R., Burris H., Monnier A., et al., On behalf of the H2H trial steering committee. The Head to Head trial: Letrozole vs. anastrozole as adjuvant treatment of postmenopausal patients with node positive breast cancer. J Clin Oncol 24 18S (2006) 582s [abstract 10672]
44. Yaffe K., Grady D., Pressman A., and Cummings S. Serum estrogen levels, cognitive performance, and risk of cognitive decline in older community women. J Am Geriatr Soc 46 (1998) 816-821
45. Jenkins V., Shilling V., Fallowfield L., Howell A., and Hutton S. Does hormone therapy for the treatment of breast cancer have a detrimental effect on memory and cognition? A pilot study. Psychooncology 13 (2004) 61-66
46. Bender C.M., Sereika S.M., Ryan C.M., et al. Memory impairments with anastrozole versus tamoxifen therapy in women with early stage breast cancer. Breast Cancer Res Treat 94 Suppl. 1 (2005) S274 [abstract 6074]
47. White R.H. The epidemiology of venous thromboembolism. Circulation 107 (2003) I4-I8
48. Nordman I.C., Spillane A.J., and Hamilton A.L. The aromatase inhibitors in early breast cancer: who, when, and why?. Med J Aust 183 (2005) 24-27
49. ATAC (Arimidex, Tamoxifen Alone or in Combination) Trialists' Group. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 359 (2002) 2131-2139
50. Oger E. Incidence of venous thromboembolism: a community-based study in Western France. Thromb Haemost 83 (2001) 657-660
51. Duffy S.R., Distler W., and On Behalf of the ATAC Trialists' Group. Gynecologic interventions during adjuvant therapy with anastrozole or tamoxifen: results from the ATAC trial. Breast Cancer Res Treat 94 Suppl. 1 (2005) S103 [abstract 2056]
52. Hori Y., Akizuki M., and Nishimura R. Comparison of adverse effects on lipid metabolism of Anastrozole with Tamoxifen in adjuvant setting for postmenopausal women with early breast cancer. Eur J Cancer 4 Suppl. (2006) 94 [abstract 172]
53. Fallowfield L., Cella D., Cuzick J., Francis S., Locker G., and Howell A. Quality of life of postmenopausal women in the Arimidex, Tamoxifen, Alone or in Combination (ATAC) adjuvant breast cancer trial. J Clin Oncol 22 (2004) 4261-4271
54. Fallowfield L.J., Bliss J.M., Porter L.S., et al. Quality of life in the intergroup exemestane study: a randomized trial of exemestane versus continued tamoxifen after 2-3 years of tamoxifen in postmenopausal women with primary breast cancer. J Clin Oncol 24 (2006) 910-917
55. Whelan T.J., Goss P.E., Ingle J.N., et al. Assessment of quality of life in MA.17: a randomized, placebo-controlled trial of letrozole after 5 years of tamoxifen in postmenopausal women. J Clin Oncol 23 (2005) 6931-6940
56. Abetz L., Barghout V., Thomas S., and Arbuckle R. Letrozole did not worsen quality of life relative to placebo in post-menopausal women with early breast cancer: results from the US subjects of the MA-17 study. Breast Cancer Res Treat 94 Suppl. 1 (2005) S100 [abstract 2047]
57. Barghout V., Abetz L., Thomas S., and Arbuckle R. Impact of letrozole on quality of life in post-menopausal women with early breast cancer: does age matter?. Breast Cancer Res Treat 94 Suppl. 1 (2005) S101 [abstract 2040]
58. Mackey J.R., and Joy A.A. Skeletal health in postmenopausal survivors of early breast cancer. Int J Cancer 114 (2005) 1010-1015
59. National Guideline Clearinghouse. Guideline synthesis: Lipid screening in adults and children. In: National Guideline Clearinghouse (NGC) [website]. Rockville, MD, October 10, 2000. Updated December 27; 2004. Available from: http://www.guideline.gov. Accessed January 6; 2006.
60. Baum M., Budzar A.U., Cuzick J., et al., ATAC Trialists' Group. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 359 (2002) 2131-2139